Chioma Chukwuemeka-Joseph (ACA) (FMVA)’s Post

View profile for Chioma Chukwuemeka-Joseph    (ACA)  (FMVA), graphic

Venture Capital | Advisory | Climate Tech | Fintech | Venture Scout

Surge's €7.5M Funding Round: A Boon for Telemedicine & African Healthcare   The successful €7.5 million fundraising by SurgeCare, a European company pioneering immune system decryption for precision medicine, caught my attention. While Surge itself isn't African, its focus on personalized healthcare solutions resonates deeply with Africa's evolving telemedicine and telehealth space.   Here's why this is exciting news: Precision medicine holds immense potential: Tailoring treatments based on individual needs can significantly improve healthcare outcomes, where access to specialized care is limited. Surge's advancements can inspire VC trends: This significant investment by Eurazeo and other partners could encourage more VC interest in telemedicine solutions across Africa, leading to increased innovation and funding. SurgeLab™M and PreCyte® offer promising applications: These innovations focused on acquiring individualized immune signatures and predicting post-operative complications align perfectly with the need for remote diagnostics and personalized care in telemedicine. A bright future for African health: Surge's success story is a testament to the growing importance of personalized healthcare solutions. I'm optimistic that this will pave the way for more telemedicine advancements in Africa, ultimately improving the health and well-being of the continent's population.   Kudos to the SurgeCare team! Their dedication to precision medicine inspires us all. #telemedicine #africa #healthcare #precisionmedicine #venturecapital

View organization page for SurgeCare, graphic

1,794 followers

Surge advances further in its pursuit of decrypting the immune system to drive precision medicine, with our successful fundraising of €7.5 million ✨ This fundraising round, led by Eurazeo and bolstered by the support of new and old strategic partners including : Boutique Venture Partners, HCVC, 50 Partners Santé, Kima Ventures, MH Innov' and Yann Fleureau, propels us closer to our ambitious objectives. We are positioned to launch of our first product, #PreCyte®, for predicting the risk of postoperative complications, and our premier laboratory, #SurgeLab™, for acquiring individualized immune signatures. Join us on this journey to unlock the secrets of the immune system and redefine precision medicine!🔥 #Surge #PrecisionMedicine #Stabl #Healthcare

To view or add a comment, sign in

Explore topics